Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: news events what matters most alzheimer’s treatment research
… In-Person Course: Regulatory-Grade Causal Research in Pharmacoepidemiology Share on: Wednesday, March … is different from prediction and description, and what the identifying conditions are. Design causal …
… What New Practical Realities Will Joint Clinical Assessments … are looking to understand the potential implications of what will emerge when the guidelines have been finalised. … initial EU JCAs. Companies could find choosing to pursue research for the larger rather than the smaller and rarer …
… Updates and Events …
… in research. Read the other two articles here. Part 1: What Factors Influence Health Equity - or Inequity? Part 3: … in advancing health equity, as their involvement has the most direct impact on meeting patients’ needs. These entities … than only certain groups can yield new and more effective treatment strategies that have greater patient adherence. By …
… Health Economics and Outcomes Research (HEOR) Strategy Plans and Gap Analyses for a Treatment Targeting Multiple Rare Diseases OPPORTUNITY Our … product in multiple phase 2 and 3 clinical trials for the treatment of numerous rare disease indications (chronic …
… Assigning Treatment Strategy Using Real-World Data A Challenge of Real … a decade in fields like HIV, cardiovascular, and cancer research. In this study we explored an alternative to … 70 years old who were just screened for breast cancer, what was the effect of stopping screening vs. continuing …
… with dementia. The prevalence is higher in Parkinson’s and Alzheimer’s disease compared to other types of … identified psychosis through medication codes, and most did not account for other life-threating conditions like …
… Economics Transcript As disease-modifying therapies for Alzheimer’s disease, or AD, enter the market, economic evaluations are … scenario using hypothetical clinical trial data for a treatment for early AD. We first compared the groups’ …
… (EMA) and US Food and Drug Administration (FDA) for cancer treatment found that the agencies use different standards to … labeling claims from both agencies. Learning objectives • What are the main characteristics of the labels granted by … when including PRO-related endpoints in cancer clinical research? And how can these challenges be overcome? • What …
… with dementia. The prevalence is higher in Parkinson’s and Alzheimer’s disease compared to other types of … identified psychosis through medication codes, and most did not account for other life-threating conditions like …